I would hope that 3rd qtr would be the bottom but I am apprehensive about whether, come the New Year, some of the other PBMs follow CVS’s lead. But, as you allude to, Spain, UK, and others should start to pick up the pace and hopefully offset and add more than the losses in the US
TC - agreed that Product Revenues will see an approximately $10million hit this quarter. But how do we off set the reduction of about $20 million that we had in milestone payments last quarter, both of these will impact cash by a minus $30million. In addition there is risk of addition inventory write offs with product sales dropping by a significant amount. I fear we dont see $1 per share until we see positive cash flow again, especially since the stock continues to sell at essentially cash on hand value.
The lawyers and courts need to save us with a big win against Hikma which will take time while our cash will fall at a fast rate.
I am hoping for traction in Europe to pick up exponentially while we finalize agreements with Italy & France (Germany?).
And a large purchase by Sarissa in the meantime would certainly help with the stock value equation !!
Market Data 
Markets 
AI
